Scanning to guide focal therapy for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a special PET/MRI scan (using a tracer called 68Ga-PSMA-11) can better identify the main tumor in men with early prostate cancer who are planning surgery. The goal is to help doctors target treatment more precisely in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to give written permission to join.
- You must have prostate cancer that is still in an early stage (doctors call it stage T2c or less) and plan to have surgery to remove the prostate.
- Your PSA blood test result must be 20 or less.
- Your biopsy must show an intermediate-risk grade (Gleason 3+4 or 4+3) in a visible MRI lesion.
- You cannot have had a bad reaction to either the PET tracer (68Ga-PSMA-11) or the MRI contrast dye.
- You must be able to lie still for the PET/MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of imaging scans (a PSMA PET scan and an MRI) to see which is better at finding prostate cancer. You may be able to join if you are scheduled for prostate removal surgery and haven't started cancer treatment yet.
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.